美国FDA将检查强生1亿剂新冠疫苗是否遭交叉污染
强生(JNJ.US)疫苗代工厂Emergent表示,目前有超过1亿剂强生新冠疫苗正等待美国食品药品管理局(FDA)重新检查。它们可能受到污染并需要销毁。
此前Emergent被FDA发现生产环境不合格,导致1,500万剂强生疫苗遭交叉污染。
Emergent行政总裁Robert Kramer出席国会众议院委员会听证会时为事件致歉,并表示位於美国马里兰州巴尔的摩(Baltimore)厂房,涉嫌混用强生及阿斯利康疫苗原材料,交叉污染的疫苗已全数销毁。他又表示,厂房已准备好足够原料重新投产。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.